Go Pro
→ Pass by August 7… or wait until 2027? (From Crypto 101 Media) (Ad)tc pixel Free OM Stock Alerts

Outset Medical (OM) Financials

Outset Medical logo
$4.27 -0.03 (-0.70%)
As of 12:27 PM Eastern
Compare
Annual Income Statements for Outset Medical

Annual Income Statements for Outset Medical

This table shows Outset Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -73 -68 -121 -132 -163 -173 -128 -82
Consolidated Net Income / (Loss)		 -50 -68 -121 -132 -163 -173 -128 -82
Net Income / (Loss) Continuing Operations		 -50 -68 -121 -132 -163 -173 -128 -82
Total Pre-Tax Income 		-50 -68 -121 -132 -163 -172 -127 -81
Total Operating Income		 -47 -70 -117 -131 -161 -170 -113 -67
Total Gross Profit		 -6.12 -18 -13 7.61 18 29 39 47
Total Revenue		 2.01 15 50 103 115 130 114 119
Operating Revenue		 2.01 15 50 103 115 130 114 119
Total Cost of Revenue		 8.12 33 63 95 98 101 75 73
Operating Cost of Revenue		 8.12 33 63 95 98 101 75 73
Total Operating Expenses		 40 53 104 138 179 199 152 113
Selling, General & Admin Expense		 6.25 8.92 31 36 41 45 43 38
Marketing Expense		 11 20 45 65 89 96 70 54
Research & Development Expense		 23 23 29 37 49 57 38 21
Total Other Income / (Expense), net		 -3.19 2.03 0.53 -1.22 -1.64 -2.50 -14 -14
Interest Expense		 4.64 4.26 4.46 1.72 4.93 13 24 22
Other Income / (Expense), net		 1.45 6.29 0.09 0.50 3.29 10 9.76 7.41
Income Tax Expense		 0.03 0.02 0.00 0.20 0.30 0.52 0.49 0.72
Basic Earnings per Share		 ($100.75) ($99.58) ($4.85) ($2.89) ($3.38) ($52.28) ($36.96) ($5.37)
Weighted Average Basic Shares Outstanding		 725K 858K 16.36K 45.59M 48.16M 3.31M 3.46M 15.21M
Diluted Earnings per Share		 ($100.75) ($99.58) ($4.85) ($2.89) ($3.38) ($52.28) ($36.96) ($5.37)
Weighted Average Diluted Shares Outstanding		 725K 858K 16.36K 45.59M 48.16M 3.31M 3.46M 15.21M
Weighted Average Basic & Diluted Shares Outstanding		 725K 858K 16.36M 45.59M 48.64M 50.51M 53.90M 18.31M

Quarterly Income Statements for Outset Medical

This table shows Outset Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -39 -40 -34 -28 -26 -26 -19 -18 -19 -19 -18
Consolidated Net Income / (Loss)		 -39 -40 -34 -28 -26 -26 -19 -18 -19 -19 -18
Net Income / (Loss) Continuing Operations		 -39 -40 -34 -28 -26 -26 -19 -18 -19 -19 -18
Total Pre-Tax Income 		-38 -40 -34 -28 -26 -26 -18 -17 -19 -19 -18
Total Operating Income		 -37 -37 -31 -24 -22 -16 -17 -16 -18 -17 -16
Total Gross Profit		 7.71 8.22 9.78 9.82 11 11 12 12 12 12 13
Total Revenue		 31 28 27 29 29 30 31 29 29 28 32
Operating Revenue		 31 28 27 29 29 30 31 29 29 28 32
Total Cost of Revenue		 23 20 18 19 19 19 20 18 17 16 18
Operating Cost of Revenue		 23 20 18 19 19 19 20 18 17 16 18
Total Operating Expenses		 45 45 41 34 33 27 29 27 30 29 29
Selling, General & Admin Expense		 10 11 13 10 9.27 8.30 9.16 8.48 12 10 11
Marketing Expense		 22 21 18 15 15 14 14 14 13 13 12
Research & Development Expense		 13 13 9.73 8.14 7.89 5.52 5.29 5.38 5.06 5.62 5.45
Total Other Income / (Expense), net		 -1.14 -2.87 -3.54 -3.92 -3.78 -9.27 -1.57 -1.62 -1.77 -1.84 -2.09
Interest Expense		 3.42 5.97 6.01 6.07 5.83 11 3.48 3.48 3.44 3.37 3.44
Other Income / (Expense), net		 2.28 3.10 2.47 2.15 2.04 1.98 1.90 1.86 1.67 1.53 1.35
Income Tax Expense		 0.11 0.16 0.15 0.18 -0.00 0.12 0.10 0.40 0.10 0.22 0.22
Basic Earnings per Share		 ($11.68) ($11.77) ($9.96) ($8.02) ($0.47) ($3.66) ($1.04) ($1.00) ($1.28) ($1.03) ($0.97)
Weighted Average Basic Shares Outstanding		 3.31M 3.39M 3.46M 3.48M 51.95M 7.04M 17.74M 17.78M 15.21M 18.37M 18.62M
Diluted Earnings per Share		 ($11.68) ($11.77) ($9.96) ($8.02) ($0.47) ($3.66) ($1.04) ($1.00) ($1.28) ($1.03) ($0.97)
Weighted Average Diluted Shares Outstanding		 3.31M 3.39M 3.46M 3.48M 51.95M 7.04M 17.74M 17.78M 15.21M 18.37M 18.62M
Weighted Average Basic & Diluted Shares Outstanding		 50.51M 51.72M 52.09M 52.54M 53.90M 17.72M 17.77M 18.15M 18.31M 18.54M 18.80M

Annual Cash Flow Statements for Outset Medical

This table details how cash moves in and out of Outset Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 20 4.25 291 -113 -139 -4.70 56 -89
Net Cash From Operating Activities		 -46 -70 -99 -130 -146 -131 -116 -46
Net Cash From Continuing Operating Activities		 -46 -70 -99 -130 -146 -131 -116 -46
Net Income / (Loss) Continuing Operations		 -50 -68 -121 -132 -163 -173 -128 -82
Consolidated Net Income / (Loss)		 -50 -68 -121 -132 -163 -173 -128 -82
Depreciation Expense		 1.07 1.48 3.16 5.16 5.17 5.81 5.73 4.34
Amortization Expense		 -0.78 -0.98 0.05 1.97 0.45 -6.37 -4.72 -2.25
Non-Cash Adjustments To Reconcile Net Income		 3.27 -0.90 25 20 33 43 36 31
Changes in Operating Assets and Liabilities, net		 -0.22 -1.60 -5.85 -26 -21 -0.77 -26 2.20
Net Cash From Investing Activities		 -69 74 3.95 -143 -66 83 104 -98
Net Cash From Continuing Investing Activities		 -69 74 3.95 -143 -66 83 104 -98
Purchase of Property, Plant & Equipment		 -1.77 -3.29 -9.08 -3.11 -8.33 -3.44 -0.91 -0.80
Purchase of Investments		 -132 -92 -33 -178 -261 -172 -157 -222
Sale and/or Maturity of Investments		 65 169 46 39 203 259 261 125
Net Cash From Financing Activities		 135 0.25 386 160 73 44 68 56
Net Cash From Continuing Financing Activities		 135 0.25 386 160 73 44 68 56
Repayment of Debt		 0.00 -0.01 -31 0.00 -31 0.00 0.00 -205
Repurchase of Common Equity		 - - - - 0.00 0.00 -0.94 0.00
Issuance of Debt		 0.00 0.00 30 0.00 96 33 67 98
Issuance of Preferred Equity		 0.00 0.00 127 0.00 0.00 0.00 0.00 162
Other Financing Activities, net		 0.32 0.44 1.19 11 8.04 10 2.28 0.64
Cash Interest Paid		 3.29 3.35 3.27 1.15 3.19 11 21 16
Cash Income Taxes Paid		 0.01 0.04 0.02 0.08 0.39 0.49 0.59 0.45

Quarterly Cash Flow Statements for Outset Medical

This table details how cash moves in and out of Outset Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 32 -36 5.68 -4.57 91 -48 -36 -3.12 -0.93 -4.44 4.44
Net Cash From Operating Activities		 -24 -46 -33 -21 -16 -26 -4.82 -6.32 -9.52 -13 -9.64
Net Cash From Continuing Operating Activities		 -24 -46 -33 -21 -16 -26 -4.82 -6.32 -9.52 -13 -9.64
Net Income / (Loss) Continuing Operations		 -39 -40 -34 -28 -26 -26 -19 -18 -19 -19 -18
Consolidated Net Income / (Loss)		 -39 -40 -34 -28 -26 -26 -19 -18 -19 -19 -18
Depreciation Expense		 1.45 1.46 1.47 1.39 1.41 1.29 1.16 1.01 0.88 0.80 0.63
Amortization Expense		 -1.27 -1.58 -1.35 -0.96 -0.83 -0.40 -0.63 -0.69 -0.54 -0.41 -0.39
Non-Cash Adjustments To Reconcile Net Income		 10 9.61 13 7.36 6.49 12 5.93 5.18 8.13 4.23 4.95
Changes in Operating Assets and Liabilities, net		 3.98 -15 -12 -0.41 2.08 -13 7.26 6.02 1.50 1.52 3.16
Net Cash From Investing Activities		 23 -59 39 16 108 -78 -31 2.97 8.59 7.90 14
Net Cash From Continuing Investing Activities		 23 -59 39 16 108 -78 -31 2.97 8.59 7.90 14
Purchase of Property, Plant & Equipment		 -1.05 -0.35 -0.12 -0.40 -0.04 -0.12 -0.29 -0.16 -0.22 -0.07 -0.11
Purchase of Investments		 -51 -99 -30 -22 -6.12 -96 -57 -40 -28 -23 -19
Sale and/or Maturity of Investments		 76 40 69 38 114 18 26 43 37 31 33
Net Cash From Financing Activities		 33 69 0.08 0.12 -0.94 56 -0.38 0.23 - 0.50 -0.09
Net Cash From Continuing Financing Activities		 33 69 0.08 0.12 -0.94 56 -0.38 0.23 - 0.50 -0.09
Repayment of Debt		 - 0.00 - - - -205 - - - -0.01 0.01
Other Financing Activities, net		 0.00 2.09 0.08 0.12 - 0.41 - 0.23 - 0.51 -0.09
Cash Interest Paid		 9.01 4.92 5.18 5.44 5.15 7.36 2.78 2.77 2.73 2.67 2.71
Cash Income Taxes Paid		 0.09 0.26 0.10 0.12 0.12 0.11 0.10 0.12 0.12 0.40 0.27

Annual Balance Sheets for Outset Medical

This table presents Outset Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 88 404 463 400 314 276 264
Total Current Assets		 80 346 410 374 291 258 251
Cash & Equivalents		 37 295 182 73 69 124 35
Short-Term Investments		 33 20 157 214 135 35 134
Accounts Receivable		 3.91 6.47 26 28 33 36 28
Inventories, net		 4.60 18 39 51 49 59 48
Prepaid Expenses		 1.06 6.19 5.53 6.60 5.70 4.53 6.00
Plant, Property, & Equipment, net		 7.90 15 13 16 13 8.13 4.67
Total Noncurrent Assets		 0.83 43 41 11 9.31 9.44 8.94
Noncurrent Note & Lease Receivables		 - - - - - - 0.00
Other Noncurrent Operating Assets		 0.83 43 41 11 9.31 9.44 8.94
Total Liabilities & Shareholders' Equity		 88 404 463 400 314 276 264
Total Liabilities		 51 75 89 154 191 249 138
Total Current Liabilities		 25 37 52 52 55 45 38
Accounts Payable		 4.96 4.95 1.76 0.60 5.83 3.86 0.55
Accrued Expenses		 4.61 11 17 20 17 10 11
Current Deferred Revenue		 0.88 3.20 6.34 8.66 12 13 14
Current Employee Benefit Liabilities		 6.96 17 25 22 19 17 11
Other Current Liabilities		 0.00 0.88 1.15 1.32 1.59 1.80 1.74
Total Noncurrent Liabilities		 26 39 38 102 136 204 100
Long-Term Debt		 22 30 30 96 130 197 96
Capital Lease Obligations		 - - - - - - 0.00
Noncurrent Deferred Revenue		 0.13 0.57 0.31 0.15 0.10 0.84 0.41
Other Noncurrent Operating Liabilities		 4.50 8.28 7.61 5.69 5.38 5.38 3.27
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -372 329 374 246 123 27 127
Total Preferred & Common Equity		 -372 329 374 246 123 27 127
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -372 329 374 246 123 27 127
Common Stock		 0.36 823 1,000 1,036 1,085 1,117 1,298
Retained Earnings		 -373 -494 -626 -789 -962 -1,090 -1,171
Accumulated Other Comprehensive Income / (Loss)		 0.02 0.00 -0.18 -0.56 0.07 0.04 0.17

Quarterly Balance Sheets for Outset Medical

This table presents Outset Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 308 346 315 293 301 289 277 249 242
Total Current Assets		 284 325 295 275 287 276 265 237 228
Cash & Equivalents		 36 32 38 33 76 40 36 31 35
Short-Term Investments		 158 195 157 142 113 145 142 126 112
Accounts Receivable		 35 36 34 34 37 35 33 25 29
Inventories, net		 48 56 62 61 56 52 49 50 47
Prepaid Expenses		 6.03 6.16 4.57 3.95 4.90 4.35 4.48 5.03 4.12
Plant, Property, & Equipment, net		 14 12 11 9.49 6.94 6.17 5.25 4.07 3.71
Total Noncurrent Assets		 10 8.90 8.52 8.13 7.71 7.06 6.63 8.67 11
Noncurrent Note & Lease Receivables		 - - - - - - - 0.08 1.70
Other Noncurrent Operating Assets		 10 8.90 8.52 8.13 7.71 7.06 6.63 8.59 9.13
Total Liabilities & Shareholders' Equity		 308 346 315 293 301 289 277 249 242
Total Liabilities		 155 253 246 245 131 134 135 138 146
Total Current Liabilities		 53 51 43 42 34 37 37 38 44
Accounts Payable		 2.88 6.77 5.26 4.30 1.17 1.45 1.72 1.44 4.46
Accrued Expenses		 16 15 12 8.91 9.77 9.76 8.06 13 14
Current Deferred Revenue		 11 13 13 13 13 14 15 13 14
Current Employee Benefit Liabilities		 22 14 11 15 8.24 9.79 11 8.75 9.07
Other Current Liabilities		 1.54 1.64 1.69 1.75 1.85 1.91 1.91 1.82 2.59
Total Noncurrent Liabilities		 102 202 203 203 97 97 97 100 102
Long-Term Debt		 97 197 197 197 94 95 96 97 98
Capital Lease Obligations		 - - - - - - - 0.06 1.15
Noncurrent Deferred Revenue		 0.10 0.19 0.13 0.08 0.80 0.59 0.68 0.37 0.30
Other Noncurrent Operating Liabilities		 5.58 5.37 5.38 5.38 2.20 1.71 1.24 2.80 3.06
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 152 93 69 48 170 155 142 112 96
Total Preferred & Common Equity		 152 93 69 48 170 155 142 112 96
Preferred Stock		 0.00 0.00 0.00 0.00 3.84 3.84 3.84 0.00 0.00
Total Common Equity		 152 93 69 48 166 151 139 112 96
Common Stock		 1,075 1,095 1,105 1,112 1,281 1,285 1,290 1,302 1,305
Retained Earnings		 -923 -1,002 -1,036 -1,064 -1,116 -1,134 -1,152 -1,190 -1,208
Accumulated Other Comprehensive Income / (Loss)		 -0.25 -0.26 -0.30 0.35 0.09 0.05 0.16 -0.07 -0.14

Annual Metrics And Ratios for Outset Medical

This table displays calculated financial ratios and metrics derived from Outset Medical's official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 651.27% 231.18% 105.47% 12.45% 13.00% -12.80% 5.09%
EBITDA Growth		 0.00% -41.71% -79.73% -7.64% -23.78% -5.29% 35.93% 44.24%
EBIT Growth		 0.00% -41.91% -83.33% -10.78% -21.31% -1.19% 35.08% 42.77%
NOPAT Growth		 0.00% -50.99% -67.08% -11.11% -23.37% -5.43% 33.22% 41.16%
Net Income Growth		 0.00% -37.20% -77.88% -8.60% -23.51% -6.04% 25.94% 36.20%
EPS Growth		 0.00% 1.16% 95.13% 40.41% -16.96% -6.04% 29.31% 85.47%
Operating Cash Flow Growth		 0.00% -51.35% -40.86% -31.56% -11.87% 9.85% 11.47% 60.17%
Free Cash Flow Firm Growth		 0.00% 0.00% -184.66% 13.21% 8.12% -10.18% 16.27% 62.78%
Invested Capital Growth		 0.00% 0.00% 1,255.22% 48.24% -14.81% -9.39% 31.88% -17.20%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 11.89% 3.46% -1.14% -0.91% -0.49%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -7.48% 1.81% 7.07% 13.24% 5.97%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -7.19% 2.63% 7.34% 12.83% 6.11%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -7.57% 0.60% 1.43% 12.02% 5.96%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -7.49% -0.13% 1.62% 9.20% 7.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -788.10% 1.46% 1.62% 10.22% -8.70%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -12.05% -5.54% -1.27% 7.12% 6.40% 13.07%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 19.62% -20.94% 9.10% 10.39%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -3.15% -32.66% -9.43% -5.57% -8.45%
Profitability Metrics		 - - - - - - - -
Gross Margin		 -304.68% -118.07% -26.11% 7.42% 15.46% 22.24% 33.92% 39.13%
EBITDA Margin		 -2,233.48% -421.28% -228.63% -119.77% -131.84% -122.84% -90.25% -47.88%
Operating Margin		 -2,320.03% -466.29% -235.24% -127.21% -139.56% -130.22% -99.72% -55.83%
EBIT Margin		 -2,247.93% -424.61% -235.05% -126.72% -136.71% -122.41% -91.14% -49.63%
Profit (Net Income) Margin		 -2,480.32% -452.97% -243.30% -128.59% -141.24% -132.54% -112.57% -68.34%
Tax Burden Percent		 100.05% 100.03% 100.00% 100.15% 100.18% 100.30% 100.39% 100.89%
Interest Burden Percent		 110.28% 106.65% 103.51% 101.32% 103.13% 107.94% 123.04% 136.49%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -414.71% -169.56% -189.15% -227.45% -137.80% -77.98%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -390.64% -155.92% -169.09% -186.63% 143.84% 127.54%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 348.30% 132.00% 136.59% 133.76% -33.17% -28.22%
Return on Equity (ROE)		 0.00% -183.31% -66.41% -37.55% -52.56% -93.69% -170.97% -106.20%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -298.06% -208.42% -173.16% -217.59% -165.29% -59.17%
Operating Return on Assets (OROA)		 0.00% -72.45% -47.69% -29.98% -36.53% -44.71% -35.15% -21.95%
Return on Assets (ROA)		 0.00% -77.29% -49.37% -30.42% -37.74% -48.41% -43.41% -30.23%
Return on Common Equity (ROCE)		 0.00% 1,831.10% 7.91% -37.55% -52.56% -93.69% -170.97% -106.20%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 18.35% -36.97% -35.27% -66.25% 0.00% -477.18% 0.00%
Net Operating Profit after Tax (NOPAT)		 -33 -49 -82 -91 -113 -119 -79 -47
NOPAT Margin		 -1,624.02% -326.40% -164.67% -89.05% -97.69% -91.15% -69.81% -39.08%
Net Nonoperating Expense Percent (NNEP)		 0.00% -93.05% -24.07% -13.64% -20.06% -40.82% -281.65% -205.53%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -32.93% -46.97% -35.40% -20.92%
Cost of Revenue to Revenue		 404.68% 218.07% 126.11% 92.58% 84.54% 77.76% 66.08% 60.87%
SG&A Expenses to Revenue		 311.56% 59.15% 61.10% 35.40% 35.12% 34.69% 38.26% 31.69%
R&D to Revenue		 1,141.80% 154.71% 57.78% 35.81% 42.34% 43.96% 33.77% 17.77%
Operating Expenses to Revenue		 2,015.35% 348.22% 209.13% 134.62% 155.02% 152.46% 133.64% 94.96%
Earnings before Interest and Taxes (EBIT)		 -45 -64 -117 -130 -158 -160 -104 -59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -45 -64 -114 -123 -152 -160 -103 -57
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 7.39 5.80 5.07 2.21 2.17 0.53
Price to Tangible Book Value (P/TBV)		 0.00 0.00 7.39 5.80 5.07 2.21 2.17 0.53
Price to Revenue (P/Rev)		 120.42 16.03 48.61 21.16 10.81 2.08 0.51 0.56
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 49.34 28.92 19.26 3.99 1.48 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 40.46 42.89 18.14 9.15 1.52 0.85 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.78 0.09 0.08 0.39 1.06 7.36 0.76
Long-Term Debt to Equity		 0.00 0.58 0.09 0.08 0.39 1.06 7.36 0.76
Financial Leverage		 0.00 -1.10 -0.89 -0.85 -0.81 -0.72 -0.23 -0.22
Leverage Ratio		 0.00 2.37 1.35 1.23 1.39 1.94 3.94 3.51
Compound Leverage Factor		 0.00 2.53 1.39 1.25 1.44 2.09 4.85 4.80
Debt to Total Capital		 0.00% 43.82% 8.28% 7.37% 28.14% 51.43% 88.04% 43.12%
Short-Term Debt to Total Capital		 0.00% 11.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 32.51% 8.28% 7.37% 28.14% 51.43% 88.04% 43.12%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 617.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -561.20% 91.72% 92.63% 71.86% 48.57% 11.96% 56.88%
Debt to EBITDA		 0.00 -0.46 -0.26 -0.24 -0.63 -0.81 -1.92 -1.68
Net Debt to EBITDA		 0.00 0.65 2.50 2.52 1.26 0.46 -0.38 1.27
Long-Term Debt to EBITDA		 0.00 -0.34 -0.26 -0.24 -0.63 -0.81 -1.92 -1.68
Debt to NOPAT		 0.00 -0.59 -0.36 -0.33 -0.85 -1.09 -2.49 -2.06
Net Debt to NOPAT		 0.00 0.83 3.47 3.39 1.70 0.62 -0.49 1.56
Long-Term Debt to NOPAT		 0.00 -0.44 -0.36 -0.33 -0.85 -1.09 -2.49 -2.06
Altman Z-Score		 0.00 -4.54 17.73 12.90 2.05 -3.80 -5.29 -5.23
Noncontrolling Interest Sharing Ratio		 0.00% 1,098.92% 111.91% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.00 3.20 9.43 7.93 7.19 5.26 5.69 6.67
Quick Ratio		 0.00 2.97 8.76 7.06 6.07 4.27 4.28 5.24
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -45 -129 -112 -103 -114 -95 -35
Operating Cash Flow to CapEx		 -2,629.78% -2,134.59% -1,090.83% -4,191.25% -1,750.50% -3,818.98% -12,752.52% -5,805.39%
Free Cash Flow to Firm to Interest Expense		 0.00 -10.68 -29.03 -65.48 -20.92 -8.97 -3.99 -1.64
Operating Cash Flow to Interest Expense		 -10.01 -16.51 -22.21 -75.96 -29.54 -10.36 -4.87 -2.14
Operating Cash Flow Less CapEx to Interest Expense		 -10.39 -17.29 -24.25 -77.77 -31.23 -10.64 -4.91 -2.18
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.17 0.20 0.24 0.27 0.37 0.39 0.44
Accounts Receivable Turnover		 0.00 3.85 9.62 6.40 4.30 4.27 3.31 3.74
Inventory Turnover		 0.00 7.15 5.48 3.30 2.15 2.01 1.38 1.36
Fixed Asset Turnover		 0.00 1.91 4.36 7.34 8.00 8.95 10.62 18.66
Accounts Payable Turnover		 0.00 6.63 12.71 28.31 82.45 31.53 15.51 32.94
Days Sales Outstanding (DSO)		 0.00 94.75 37.94 57.04 84.90 85.46 110.12 97.68
Days Inventory Outstanding (DIO)		 0.00 51.02 66.60 110.60 169.63 181.27 263.83 268.51
Days Payable Outstanding (DPO)		 0.00 55.06 28.71 12.89 4.43 11.58 23.54 11.08
Cash Conversion Cycle (CCC)		 0.00 90.71 75.83 154.75 250.09 255.15 350.41 355.11
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 -3.76 43 64 55 50 66 54
Invested Capital Turnover		 0.00 -8.02 2.52 1.90 1.94 2.50 1.97 2.00
Increase / (Decrease) in Invested Capital		 0.00 -3.76 47 21 -9.53 -5.15 16 -11
Enterprise Value (EV)		 0.00 610 2,142 1,861 1,056 198 97 -5.36
Market Capitalization		 242 242 2,427 2,171 1,247 272 58 67
Book Value per Share		 $0.00 ($433.78) $7.70 $7.94 $5.09 $2.45 $0.51 $6.99
Tangible Book Value per Share		 $0.00 ($433.78) $7.70 $7.94 $5.09 $2.45 $0.51 $6.99
Total Capital		 0.00 66 358 404 342 253 224 223
Total Debt		 0.00 29 30 30 96 130 197 96
Total Long-Term Debt		 0.00 22 30 30 96 130 197 96
Net Debt		 0.00 -41 -285 -310 -191 -73 39 -73
Capital Expenditures (CapEx)		 1.77 3.29 9.08 3.11 8.33 3.44 0.91 0.80
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -7.84 -5.65 19 34 33 54 44
Debt-free Net Working Capital (DFNWC)		 0.00 62 309 358 322 236 213 213
Net Working Capital (NWC)		 0.00 55 309 358 322 236 213 213
Net Nonoperating Expense (NNE)		 17 19 39 41 50 54 49 35
Net Nonoperating Obligations (NNO)		 0.00 -41 -285 -310 -191 -73 39 -73
Total Depreciation and Amortization (D&A)		 0.29 0.50 3.21 7.13 5.62 -0.56 1.01 2.09
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -52.01% -11.32% 18.15% 29.64% 24.98% 47.64% 37.08%
Debt-free Net Working Capital to Revenue		 0.00% 412.76% 619.24% 349.03% 278.83% 180.94% 187.22% 178.49%
Net Working Capital to Revenue		 0.00% 363.02% 619.24% 349.03% 278.83% 180.94% 187.22% 178.49%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($4.85) ($2.89) ($3.38) ($52.20) ($2.46) ($5.37)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 42.81M 47.41M 48.16M 3.31M 51.95M 15.21M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($4.85) ($2.89) ($3.38) ($52.20) ($2.46) ($5.37)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 42.81M 47.41M 48.16M 3.31M 51.95M 15.21M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($4.85) ($2.89) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 16.36M 45.59M 48.64M 3.37M 53.90M 18.31M
Normalized Net Operating Profit after Tax (NOPAT)		 -33 -49 -82 -91 -113 -119 -79 -47
Normalized NOPAT Margin		 -1,624.02% -326.40% -164.67% -89.05% -97.69% -91.15% -69.81% -39.08%
Pre Tax Income Margin		 -2,479.07% -452.84% -243.30% -128.40% -140.98% -132.14% -112.13% -67.74%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 -9.73 -15.04 -26.33 -75.81 -31.97 -12.59 -4.34 -2.74
NOPAT to Interest Expense		 -7.03 -11.56 -18.44 -53.27 -22.85 -9.38 -3.32 -2.16
EBIT Less CapEx to Interest Expense		 -10.11 -15.81 -28.37 -77.63 -33.66 -12.86 -4.38 -2.78
NOPAT Less CapEx to Interest Expense		 -7.41 -12.33 -20.48 -55.09 -24.54 -9.65 -3.36 -2.20
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.73% 0.00%

Quarterly Metrics And Ratios for Outset Medical

This table displays calculated financial ratios and metrics derived from Outset Medical's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 50,204,570.00 50,204,570.00 51,722,375.00 52,089,795.00 - 53,896,936.00 17,722,310.00 17,766,193.00 - 18,311,626.00 18,537,241.00
DEI Adjusted Shares Outstanding		 3,346,971.00 3,346,971.00 3,448,158.00 3,472,653.00 - 3,593,129.00 17,722,310.00 17,766,193.00 - 18,311,626.00 18,537,241.00
DEI Earnings Per Adjusted Shares Outstanding		 -11.53 -11.93 -9.99 -8.05 - -7.18 -1.05 -1.00 - -1.04 -0.97
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -4.69% -15.83% -24.01% -5.59% -3.41% 5.62% 14.72% 2.67% -2.01% -6.35% 0.69%
EBITDA Growth		 10.95% 17.25% 31.45% 50.74% 44.86% 60.12% 48.77% 35.86% 18.87% -10.93% 2.45%
EBIT Growth		 11.94% 17.20% 30.67% 49.42% 43.49% 57.35% 47.12% 35.65% 19.49% -6.72% 4.28%
NOPAT Growth		 6.20% 15.12% 29.24% 47.55% 41.48% 55.57% 45.18% 33.67% 19.36% -3.17% 7.05%
Net Income Growth		 6.86% 9.16% 21.78% 39.50% 33.58% 35.45% 46.19% 36.16% 23.98% 26.39% 3.00%
EPS Growth		 6.86% 9.16% 21.78% 39.50% 37.33% 68.90% 89.56% 87.53% 82.70% 71.86% 6.73%
Operating Cash Flow Growth		 29.17% -2.58% -18.31% 39.50% 32.54% 44.10% 85.53% 69.27% 42.26% 49.95% -99.77%
Free Cash Flow Firm Growth		 -14.46% -20.72% -257.90% -494.15% -48.28% 7.93% 81.41% 96.96% 96.55% 147.76% 200.42%
Invested Capital Growth		 -9.39% -0.72% 24.23% 26.48% 31.88% 18.84% -7.40% -14.59% -17.20% -30.68% -26.82%
Revenue Q/Q Growth		 0.48% -7.67% -2.77% 4.67% 2.79% 0.97% 5.60% -6.33% -1.89% -3.50% 13.54%
EBITDA Q/Q Growth		 19.15% 2.76% 16.97% 24.53% 9.50% 29.68% -6.67% 5.52% -14.48% 3.84% 6.20%
EBIT Q/Q Growth		 18.21% 3.58% 16.33% 23.34% 8.64% 27.22% -3.74% 6.71% -14.31% 3.53% 6.95%
NOPAT Q/Q Growth		 17.82% 1.18% 16.66% 22.51% 8.30% 24.98% -2.84% 6.24% -11.48% 4.03% 7.35%
Net Income Q/Q Growth		 16.41% -3.48% 13.74% 18.91% 8.24% -0.57% 28.09% 3.79% -9.27% 2.63% 5.24%
EPS Q/Q Growth		 16.41% -3.48% 13.74% 18.91% 14.55% 50.54% 71.58% 3.85% -28.00% 19.53% 5.83%
Operating Cash Flow Q/Q Growth		 28.11% -87.84% 27.39% 38.30% 19.84% -55.65% 81.21% -31.04% -50.65% -34.90% 24.98%
Free Cash Flow Firm Q/Q Growth		 -299.75% -20.87% -39.22% 11.67% 0.23% 24.95% 71.89% 85.55% -13.19% 1,138.79% -40.90%
Invested Capital Q/Q Growth		 -9.43% 27.01% 12.13% -1.94% -5.57% 14.46% -12.63% -9.55% -8.45% -4.18% -7.77%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 25.28% 29.16% 35.72% 34.26% 36.47% 37.19% 37.77% 39.38% 42.36% 43.41% 41.99%
EBITDA Margin		 -114.38% -120.46% -102.87% -74.17% -65.30% -45.48% -45.94% -46.33% -54.06% -53.87% -44.51%
Operating Margin		 -122.44% -131.04% -112.33% -83.16% -74.18% -55.12% -53.68% -53.73% -61.05% -60.72% -49.55%
EBIT Margin		 -114.96% -120.04% -103.30% -75.66% -67.25% -48.48% -47.62% -47.43% -55.26% -55.24% -45.27%
Profit (Net Income) Margin		 -126.53% -141.81% -125.80% -97.47% -87.01% -86.66% -59.01% -60.61% -67.50% -68.11% -56.85%
Tax Burden Percent		 100.29% 100.41% 100.44% 100.66% 99.98% 100.45% 100.56% 102.32% 100.49% 101.16% 101.24%
Interest Burden Percent		 109.74% 117.65% 121.24% 127.98% 129.39% 177.97% 123.23% 124.90% 121.57% 121.89% 124.03%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -213.86% -181.19% -143.38% -107.53% -102.51% -64.42% -65.80% -70.22% -85.28% -78.74% -72.04%
ROIC Less NNEP Spread (ROIC-NNEP)		 -204.44% -165.76% -122.55% -77.79% -42.63% -41.54% -50.34% -48.23% -43.24% -69.51% -61.85%
Return on Net Nonoperating Assets (RNNOA)		 146.53% 97.93% 60.38% 29.45% 9.83% 19.74% 19.64% 15.61% 9.57% 38.16% 33.91%
Return on Equity (ROE)		 -67.34% -83.26% -83.00% -78.08% -92.68% -44.69% -46.17% -54.61% -75.71% -40.57% -38.13%
Cash Return on Invested Capital (CROIC)		 -217.59% -179.68% -186.60% -168.62% -165.29% -111.37% -73.45% -61.48% -59.17% -37.89% -50.52%
Operating Return on Assets (OROA)		 -41.99% -42.36% -37.07% -28.92% -25.94% -17.26% -18.83% -19.98% -24.44% -23.59% -20.08%
Return on Assets (ROA)		 -46.21% -50.04% -45.14% -37.25% -33.55% -30.86% -23.34% -25.53% -29.85% -29.09% -25.22%
Return on Common Equity (ROCE)		 -67.34% -83.26% -83.00% -78.08% -92.68% -44.04% -45.37% -53.50% -75.71% -40.02% -37.54%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -181.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -26 -26 -22 -17 -15 -11 -12 -11 -12 -12 -11
NOPAT Margin		 -85.71% -91.73% -78.63% -58.21% -51.93% -38.58% -37.57% -37.61% -42.74% -42.51% -34.69%
Net Nonoperating Expense Percent (NNEP)		 -9.42% -15.43% -20.83% -29.74% -59.88% -22.89% -15.46% -21.99% -42.04% -9.23% -10.18%
Return On Investment Capital (ROIC_SIMPLE)		 -10.33% -8.91% -8.11% -6.81% -6.83% -4.35% -4.73% -4.65% -5.53% -5.68% -5.62%
Cost of Revenue to Revenue		 74.72% 70.84% 64.28% 65.74% 63.53% 62.81% 62.23% 60.62% 57.64% 56.59% 58.01%
SG&A Expenses to Revenue		 33.89% 40.63% 46.31% 35.24% 31.45% 27.89% 29.16% 28.80% 41.30% 36.31% 35.90%
R&D to Revenue		 41.08% 44.86% 35.54% 28.39% 26.77% 18.54% 16.83% 18.27% 17.51% 20.16% 17.23%
Operating Expenses to Revenue		 147.72% 160.21% 148.04% 117.42% 110.66% 92.31% 91.45% 93.11% 103.41% 104.13% 91.54%
Earnings before Interest and Taxes (EBIT)		 -35 -34 -28 -22 -20 -14 -15 -14 -16 -15 -14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -35 -34 -28 -21 -19 -14 -14 -14 -16 -15 -14
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.21 1.20 2.90 0.74 2.17 0.24 2.26 1.81 0.53 0.63 0.83
Price to Tangible Book Value (P/TBV)		 2.21 1.20 2.90 0.74 2.17 0.24 2.26 1.81 0.53 0.63 0.83
Price to Revenue (P/Rev)		 2.08 0.89 1.71 0.31 0.51 0.34 2.85 2.09 0.56 0.60 0.68
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 3.99 1.29 2.85 0.82 1.48 0.00 3.89 2.90 0.00 0.20 0.66
Enterprise Value to Revenue (EV/Rev)		 1.52 0.65 1.73 0.50 0.85 0.00 2.14 1.43 0.00 0.09 0.27
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.06 2.11 2.87 4.12 7.36 0.55 0.61 0.67 0.76 0.87 1.03
Long-Term Debt to Equity		 1.06 2.11 2.87 4.12 7.36 0.55 0.61 0.67 0.76 0.87 1.03
Financial Leverage		 -0.72 -0.59 -0.49 -0.38 -0.23 -0.48 -0.39 -0.32 -0.22 -0.55 -0.55
Leverage Ratio		 1.94 2.29 2.58 3.00 3.94 2.46 2.70 3.00 3.51 1.96 2.12
Compound Leverage Factor		 2.12 2.69 3.13 3.84 5.10 4.38 3.33 3.74 4.27 2.38 2.62
Debt to Total Capital		 51.43% 67.86% 74.17% 80.48% 88.04% 35.65% 37.99% 40.15% 43.12% 46.48% 50.63%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 51.43% 67.86% 74.17% 80.48% 88.04% 35.65% 37.99% 40.15% 43.12% 46.48% 50.63%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 1.46% 1.54% 1.61% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 48.57% 32.14% 25.83% 19.52% 11.96% 62.89% 60.47% 58.23% 56.88% 53.52% 49.37%
Debt to EBITDA		 -0.81 -1.29 -1.41 -1.67 -1.92 -1.14 -1.38 -1.57 -1.68 -1.65 -1.69
Net Debt to EBITDA		 0.46 0.20 -0.02 -0.18 -0.38 1.15 1.30 1.37 1.27 1.02 0.83
Long-Term Debt to EBITDA		 -0.81 -1.29 -1.41 -1.67 -1.92 -1.14 -1.38 -1.57 -1.68 -1.65 -1.69
Debt to NOPAT		 -1.09 -1.72 -1.87 -2.19 -2.49 -1.45 -1.72 -1.92 -2.06 -2.06 -2.14
Net Debt to NOPAT		 0.62 0.26 -0.02 -0.24 -0.49 1.46 1.62 1.67 1.56 1.27 1.05
Long-Term Debt to NOPAT		 -1.09 -1.72 -1.87 -2.19 -2.49 -1.45 -1.72 -1.92 -2.06 -2.06 -2.14
Altman Z-Score		 -2.49 -2.79 -3.09 -3.90 -4.29 -3.77 -2.74 -3.45 -4.69 -5.15 -5.45
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 1.46% 1.72% 2.02% 0.00% 1.36% 1.53%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.26 6.42 6.80 6.49 5.69 8.37 7.47 7.09 6.67 6.29 5.19
Quick Ratio		 4.27 5.20 5.27 4.95 4.28 6.60 5.93 5.65 5.24 4.84 4.02
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -21 -25 -35 -31 -31 -23 -6.57 -0.95 -1.07 11 6.60
Operating Cash Flow to CapEx		 -2,321.18% -12,969.49% -27,779.17% -5,207.09% -38,344.19% -20,864.23% -1,651.71% -3,950.00% -4,269.51% -19,760.00% -8,680.18%
Free Cash Flow to Firm to Interest Expense		 -6.15 -4.25 -5.88 -5.14 -5.35 -2.08 -1.89 -0.27 -0.31 3.31 1.92
Operating Cash Flow to Interest Expense		 -7.15 -7.69 -5.55 -3.39 -2.83 -2.28 -1.39 -1.82 -2.77 -3.81 -2.80
Operating Cash Flow Less CapEx to Interest Expense		 -7.46 -7.75 -5.57 -3.45 -2.84 -2.29 -1.47 -1.86 -2.83 -3.83 -2.83
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.37 0.35 0.36 0.38 0.39 0.36 0.40 0.42 0.44 0.43 0.44
Accounts Receivable Turnover		 4.27 3.53 3.28 3.29 3.31 3.14 3.46 3.57 3.74 3.78 3.67
Inventory Turnover		 2.01 1.82 1.58 1.44 1.38 1.32 1.33 1.35 1.36 1.32 1.38
Fixed Asset Turnover		 8.95 9.22 9.16 9.86 10.62 12.20 14.00 16.29 18.66 21.35 23.85
Accounts Payable Turnover		 31.53 21.52 22.37 22.08 15.51 18.59 22.63 24.85 32.94 53.45 23.26
Days Sales Outstanding (DSO)		 85.46 103.29 111.33 110.95 110.12 116.15 105.57 102.17 97.68 96.55 99.33
Days Inventory Outstanding (DIO)		 181.27 200.47 231.72 252.76 263.83 275.78 274.09 270.15 268.51 275.62 264.86
Days Payable Outstanding (DPO)		 11.58 16.96 16.32 16.53 23.54 19.63 16.13 14.69 11.08 6.83 15.69
Cash Conversion Cycle (CCC)		 255.15 286.80 326.73 347.19 350.41 372.30 363.53 357.64 355.11 365.34 348.49
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 50 63 71 69 66 75 66 59 54 52 48
Invested Capital Turnover		 2.50 1.98 1.82 1.85 1.97 1.67 1.75 1.87 2.00 1.85 2.08
Increase / (Decrease) in Invested Capital		 -5.15 -0.46 14 15 16 12 -5.24 -10 -11 -23 -18
Enterprise Value (EV)		 198 81 201 57 97 -51 255 172 -5.36 11 32
Market Capitalization		 272 111 199 35 58 40 340 251 67 70 80
Book Value per Share		 $2.45 $27.47 $1.33 $0.92 $0.51 $3.08 $8.52 $7.80 $6.99 $6.10 $5.20
Tangible Book Value per Share		 $2.45 $27.47 $1.33 $0.92 $0.51 $3.08 $8.52 $7.80 $6.99 $6.10 $5.20
Total Capital		 253 290 266 245 224 264 250 238 223 209 195
Total Debt		 130 197 197 197 197 94 95 96 96 97 99
Total Long-Term Debt		 130 197 197 197 197 94 95 96 96 97 99
Net Debt		 -73 -30 2.15 22 39 -95 -89 -83 -73 -60 -48
Capital Expenditures (CapEx)		 1.05 0.35 0.12 0.40 0.04 0.12 0.29 0.16 0.22 0.07 0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 33 48 57 57 54 63 55 49 44 42 37
Debt-free Net Working Capital (DFNWC)		 236 275 252 233 213 252 239 228 213 199 184
Net Working Capital (NWC)		 236 275 252 233 213 252 239 228 213 199 184
Net Nonoperating Expense (NNE)		 12 14 13 11 10 14 6.74 6.77 7.15 7.13 7.01
Net Nonoperating Obligations (NNO)		 -73 -30 2.15 22 39 -95 -89 -83 -73 -60 -48
Total Depreciation and Amortization (D&A)		 0.18 -0.12 0.12 0.43 0.58 0.89 0.53 0.32 0.35 0.38 0.24
Debt-free, Cash-free Net Working Capital to Revenue		 24.98% 38.22% 48.83% 49.87% 47.64% 54.94% 45.75% 41.05% 37.08% 36.06% 31.21%
Debt-free Net Working Capital to Revenue		 180.94% 219.64% 216.19% 202.95% 187.22% 218.90% 200.05% 189.83% 178.49% 169.32% 156.16%
Net Working Capital to Revenue		 180.94% 219.64% 216.19% 202.95% 187.22% 218.90% 200.05% 189.83% 178.49% 169.32% 156.16%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($175.20) ($11.70) ($9.90) ($8.25) ($0.47) ($3.66) ($1.04) ($1.00) ($1.28) ($1.03) ($0.97)
Adjusted Weighted Average Basic Shares Outstanding		 220.33K 3.39M 3.46M 3.37M 51.95M 7.04M 17.74M 17.78M 15.21M 18.37M 18.62M
Adjusted Diluted Earnings per Share		 ($175.20) ($11.70) ($9.90) ($8.25) ($0.47) ($3.66) ($1.04) ($1.00) ($1.28) ($1.03) ($0.97)
Adjusted Weighted Average Diluted Shares Outstanding		 220.33K 3.39M 3.46M 3.37M 51.95M 7.04M 17.74M 17.78M 15.21M 18.37M 18.62M
Adjusted Basic & Diluted Earnings per Share		 ($175.20) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($1.28) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 3.37M 3.45M 3.47M 3.50M 53.90M 17.72M 17.77M 18.15M 18.31M 18.54M 18.80M
Normalized Net Operating Profit after Tax (NOPAT)		 -26 -26 -22 -17 -15 -11 -12 -11 -12 -12 -11
Normalized NOPAT Margin		 -85.71% -91.73% -78.63% -58.21% -51.93% -38.58% -37.57% -37.61% -42.74% -42.51% -34.69%
Pre Tax Income Margin		 -126.16% -141.23% -125.25% -96.83% -87.02% -86.27% -58.68% -59.24% -67.17% -67.33% -56.15%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -10.26 -5.67 -4.71 -3.57 -3.40 -1.28 -4.31 -4.02 -4.64 -4.57 -4.16
NOPAT to Interest Expense		 -7.65 -4.33 -3.58 -2.75 -2.63 -1.02 -3.40 -3.18 -3.59 -3.52 -3.19
EBIT Less CapEx to Interest Expense		 -10.57 -5.73 -4.73 -3.64 -3.41 -1.29 -4.39 -4.06 -4.70 -4.59 -4.19
NOPAT Less CapEx to Interest Expense		 -7.96 -4.39 -3.60 -2.82 -2.63 -1.03 -3.48 -3.23 -3.65 -3.53 -3.22
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -0.73% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Outset Medical (NASDAQ: OM) continues to operate with a strong liquidity cushion, but the latest quarter shows the company is still losing money and burning cash. In Q1 2026, revenue was modestly lower than the prior quarter and the company reported a net loss of $19.0 million. The balance sheet remains sizable, with $156.7 million in cash and short-term investments combined, but leverage is still meaningful and operating performance remains under pressure.

What stands out most is that Outset Medical’s revenue has been relatively stable for the last several quarters, but profitability has not improved enough to turn the business cash-generative. Gross margin has held in the low-40% range, while operating expenses continue to exceed gross profit by a wide margin. The good news is that liquidity is still healthy; the concern is that cash from operations remains negative.

  • Outset Medical ended Q1 2026 with about $156.7 million in cash and short-term investments, giving it a sizable liquidity reserve.
  • Total current assets of $236.7 million still comfortably exceed current liabilities of $37.6 million.
  • Revenue in Q1 2026 was $27.9 million, roughly in line with the recent run rate seen throughout 2025 and 2024.
  • Gross profit in Q1 2026 was $12.1 million, with gross margin near 43%, which is relatively consistent with prior quarters.
  • Investing activity added cash in Q1 2026 as investment maturities exceeded new purchases, helping offset operating losses.
  • Long-term debt stood at $96.9 million in Q1 2026, so the capital structure still includes a meaningful debt load.
  • Inventory remained elevated at $49.7 million, suggesting working capital is still tied up in product stock.
  • Shares outstanding have varied widely across periods, so per-share trends can be influenced by equity issuance or restructuring activity.
  • Q1 2026 net loss was $19.0 million, and the company has remained unprofitable for years.
  • Cash from operations was negative $12.8 million in Q1 2026, showing the core business is still consuming cash.
  • Operating expenses of $29.0 million exceeded gross profit of $12.1 million by a wide margin.
  • Interest expense remains heavy at $3.4 million in Q1 2026, adding pressure to already weak earnings.
  • Compared with Q1 2024, total liabilities have fallen, but equity has also been volatile, reflecting a history of losses and capital actions.

Longer-term trend: Outset Medical’s quarterly revenue has generally hovered around the high-$20 million to low-$30 million range, but profitability has not materially improved. Losses have narrowed from the very large deficits seen in 2024, yet the company still has not crossed into positive operating income or positive free cash flow. That makes the balance sheet and cash runway the key story for investors, not earnings power.

Bottom line: OM appears to have enough liquidity for now, but investors should focus on whether management can improve operating leverage and reduce cash burn. Without sustained margin improvement or a sharper reduction in expenses, the company may continue to rely on its balance sheet to fund operations.

08/20/26 12:48 PM ETAI Generated. May Contain Errors.

Outset Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Outset Medical's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Outset Medical's net income appears to be on an upward trend, with a most recent value of -$81.65 million in 2025, rising from -$49.78 million in 2018. The previous period was -$127.98 million in 2024. Check out Outset Medical's forecast to explore projected trends and price targets.

Outset Medical's total operating income in 2025 was -$66.71 million, based on the following breakdown:
  • Total Gross Profit: $46.75 million
  • Total Operating Expenses: $113.46 million

Over the last 7 years, Outset Medical's total revenue changed from $2.01 million in 2018 to $119.48 million in 2025, a change of 5,853.0%.

Outset Medical's total liabilities were at $137.54 million at the end of 2025, a 44.8% decrease from 2024, and a 169.1% increase since 2019.

In the past 6 years, Outset Medical's cash and equivalents has ranged from $35.01 million in 2025 to $294.97 million in 2020, and is currently $35.01 million as of their latest financial filing in 2025.

Over the last 7 years, Outset Medical's book value per share changed from 0.00 in 2018 to 6.99 in 2025, a change of 699.3%.


Related Companies

Financial statements for NASDAQ:OM last updated on 8/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Look at this $5 stock’s address
A small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, ...
Freedom Financial | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
23,281 stocks. Only ONE survived.
One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...
Monument Traders Alliance | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel